124 related articles for article (PubMed ID: 578467)
1. Pharmacokinetics and bioavailability of diltiazem (CRD-401) in dog.
Kohno K; Takeuchi Y; Etoh A; Noda K
Arzneimittelforschung; 1977 Jul; 27(7):1424-8. PubMed ID: 578467
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic model of diltiazem.
Kölle EU; Ochs HR; Vollmer KO
Arzneimittelforschung; 1983; 33(7):972-7. PubMed ID: 6684932
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of diltiazem in man.
Rovei V; Gomeni R; Mitchard M; Larribaud J; Blatrix C; Thebault JJ; Morselli PL
Acta Cardiol; 1980; 35(1):35-45. PubMed ID: 6967667
[TBL] [Abstract][Full Text] [Related]
4. Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog.
Nakamura S; Suzuki T; Sugawara Y; Usuki S; Ito Y; Kume T; Yoshikawa M; Endo H; Ohashi M; Harigaya S
Arzneimittelforschung; 1987 Nov; 37(11):1244-52. PubMed ID: 3440032
[TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and absolute bioavailability of diltiazem in humans.
Ochs HR; Knüchel M
Klin Wochenschr; 1984 Apr; 62(7):303-6. PubMed ID: 6727272
[TBL] [Abstract][Full Text] [Related]
7. Effects of diltiazem Hydrochloride (CRD-401) on renal hemodynamics of dogs.
Ishikawa H; Matsushima M; Matsui H; Honjo A; Hayashi M; Shindo T; Morifuji T; Okaybayashi M
Arzneimittelforschung; 1978; 28(3):402-6. PubMed ID: 580748
[TBL] [Abstract][Full Text] [Related]
8. Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers.
De Bernardis E; Candido P; Lorefice R; Picari M; Rizza V
Arzneimittelforschung; 1992 Jan; 42(1):25-7. PubMed ID: 1586376
[TBL] [Abstract][Full Text] [Related]
9. Effects of diltiazem hydrochloride (CRD-401) on hepatic, superior mesenteric and femoral hemodynamics.
Ishikawa H; Matsushima A; Matsui H; Shindo T; Morifuji T; Okabayashi M
Arzneimittelforschung; 1978; 28(3):400-2. PubMed ID: 580747
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers.
Korhonen O; Kanerva H; Vidgren M; Urtti A; Ketolainen J
J Control Release; 2004 Mar; 95(3):515-20. PubMed ID: 15023462
[TBL] [Abstract][Full Text] [Related]
11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.
Dohoo SE; Tasker RA
Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T
Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672
[TBL] [Abstract][Full Text] [Related]
14. Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs.
Nakamura S; Ohashi M; Suzuki T; Sugawara Y; Usuki S; Takaiti O
Arzneimittelforschung; 1989 Sep; 39(9):1100-8. PubMed ID: 2590259
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs.
Löbenberg R; Kim JS; Amidon GL
Eur J Pharm Biopharm; 2005 May; 60(1):17-23. PubMed ID: 15848051
[TBL] [Abstract][Full Text] [Related]
16. Development and pharmacokinetics of a new sustained-release formulation of diltiazem.
Thiercelin JF; Necciari J; Caplain H; Cournot A; Combes M; Desmolin H; Flouvat B
J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S31-7. PubMed ID: 1706011
[TBL] [Abstract][Full Text] [Related]
17. In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride.
al-Suwayeh SA; el-Helw AR; al-Mesned AF; Bayomi MA; el-Gorashi AS
Boll Chim Farm; 2003; 142(1):14-20. PubMed ID: 12680034
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of a controlled release amoxicillin formulation.
Arancibia A; González G; Icarte A; Arancibia M; Arancibia P
Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):97-100. PubMed ID: 3557736
[TBL] [Abstract][Full Text] [Related]
19. [Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren].
Honorato J; Montes B; Suárez J; Lucero ML; Valiente R
Rev Med Univ Navarra; 1992; 37(1):7-16. PubMed ID: 1626168
[TBL] [Abstract][Full Text] [Related]
20. In vivo performance of controlled release pellets of diltiazem HCl.
Nisarur-ur-Rahman ; K H Y; Jia Woei W
Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
